The Source Blog
Recent Action in Pharmaceuticals
Introduced: 2020 Status: Enacted
Concurrent Resolution Encouraging Congressional Action on Prescription Drug Prices. Urges the United States Congress to promote innovative, market-based solutions and take specific steps to address escalating prescription drug prices.
HB 207 – Utah
Introduced: 2020 Status: Enacted
Insulin Access Amendments. This bill creates mechanisms to increase Utahns’ access to affordable insulin. This bill: creates an incentive for health benefit plans to reduce the required copayments for insulin; directs the Insurance Department to …
HB 263 – Utah
Introduced: 2020 Status: Inactive / Dead
Notice of Drug Price Increase. This bill requires a prescription drug manufacturer to provide notice of certain drug cost increases and requires the Insurance Department to publish related information.
SB 138 – Utah
Introduced: 2020 Status: Enacted
Pharmacy Benefit Manager Revisions. Prohibits a pharmacy benefit manager from prohibiting certain actions by an in-network pharmacy; prohibits a pharmacy benefit manager from charging an insured customer more for use of a pharmacy that offers …
SB 230 – Utah
Introduced: 2020 Status: Inactive / Dead
This bill creates the Prescription Drug Price Transparency Act and the Pharmaceutical Development and Marketing Act and amends the Insurance Code.
HB 272 – Utah
Introduced: 2020 Status: Enacted
This bill renames the Pharmacy Benefit Manager Licensing Act as the Pharmacy Benefits Act. Prohibits a pharmacy benefit manager from: prohibiting or penalizing a pharmacist’s disclosure of certain information regarding a prescription device; etc.
S 2776 – Massachusetts
Introduced: 2020 Status: In Process
For legislation relative to healthcare consumer health options and increased care efficiency. The commission shall require a manufacturer of a prescribed drug specified in subsection (b) to disclose to the commission within a reasonable time …
Next | See all Legislation Records
District Court: District Court of Western District of Oklahoma Status: Pending
The 2019 Oklahoma law, Patient’s Right to Pharmacy Choice Act, targets PBM conflict of interest by prohibiting higher reimbursement rates for PBM-owned pharmacies and bans …
State of Ohio v. OptumRx – Ohio
District Court: Ohio Court of Common Pleas (Franklin County) Status: Pending
On March 15, 2019, Ohio’s attorney general Dave Yost sued OptumRx in Ohio state court, claiming that between 2015 and 2018, the PBM failed to pass …
Minnesota v. Sanofi-Aventis U.S. LLC – Minnesota
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in …
Pharm. Care Mgmt. Ass’n v. Tufte – North Dakota
District Court: District of North Dakota Status: Pending
Trade association representing pharmacy benefit managers (PBMs) brought action against North Dakota state officials in their official capacities, alleging that Employee Retirement Income Security Act …
Pharm. Care Mgmt. Ass’n v. Gerhart – Iowa
District Court: Southern District of Iowa Status: Decided
Trade association representing pharmacy benefits managers (PBM) brought action against State of Iowa, seeking declaration that statute that regulated how PBMs established generic drug pricing …
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al. – California
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of …
Federal Trade Commission v. Actavis, Inc. – Georgia
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims …
Next | See all Litigation Records
News & Opinions
Articles & Reports
NEJM May 7, 2020
Journal of Health Economics May 1, 2020
Annals of Internal Medicine April 21, 2020
Trends in Pharmaceuticals
State Pharmaceutical Legislation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
2019 Drug Pricing Transparency Legislation
Pharmaceutical price transparency legislation requires disclosures from drug manufacturers and insurers to help lawmakers and the public better understand how drugs are priced and how those prices affect insurance premiums. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmaceutical Rate-Setting Legislation
Rate setting legislation either establishes the price of a prescription drug or sets the maximum amount a payer can pay for a drug. Click on highlighted states to see rate-setting legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Importation Legislation
Click on highlighted states to see drug importation legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Price Gouging Prohibition Legislation
Price gouging prohibitions typically empower the state Attorney General to act if the price of a drug is raised above a threshold. Click on highlighted states to see legislation considered in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmacy Benefit Manager Regulation Legislation
Legislation to regulate Pharmacy Benefit Managers (PBMs) typically include provisions that 1) require PBMs to register with the state, 2) mandate disclosures by PBMs, or 3) prevent PBMs from incentivizing the use of mail-order pharmacies. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered